Longevity medicine experts

Longevity medicine targets the cellular and metabolic mechanisms behind age-related decline, extending healthspan rather than simply adding years to lifespan.

2 experts, updated 22 Oct 2026

The experts 2

Dr Patrick E. SewellFounder and Chief Science OfficerGene and cell therapy delivery, from the laboratory to the patient

Sauny SewellDirector of Clinical AffairsPatient care and long-term follow-up in gene therapy and healthspan medicine

What our longevity medicine experts do

Longevity work at Triple Helix Science starts with the mechanisms behind age-related decline at cell and system level: mitochondrial efficiency and cellular energy, autophagy, genomic stability and telomere integrity. From that mechanism work the specialists build a therapeutic protocol, document it as protected intellectual property, and carry it through into human trials. Because Triple Helix Science works alongside its metabolic health, neurodegeneration and muscle biology programmes, a longevity protocol is assessed against cellular energy, brain health and muscle function rather than a single marker. Triple Helix Science has reported a completed Phase 1 human trial showing reversal of dementia progression.

How they work

The longevity medicine experts at Triple Helix Science treat ageing as systemic, which changes what counts as an endpoint. Decline in one organ system accelerates decline in others, so an intervention that improves one marker while the rest of the system keeps falling is not counted as a result. The measure held to is healthspan, years lived in good physical and cognitive health, not lifespan. Protocol development and the IP behind it are held in house, which is what allows a single intervention to be designed across more than one therapeutic area instead of assembled from separate programmes.

When to bring them in

Longevity medicine experts are brought in by governments, sovereign health systems, research universities, sovereign wealth funds and enterprise pharmaceutical organisations, usually where an ageing population and chronic disease burden are being treated as a national problem rather than an individual one. Triple Helix Science works at that level by design and does not operate as a direct-to-consumer provider. The work suits partners prepared to move from reactive symptom management towards predictive, genome-based intervention, and to carry a protocol through development and human trials rather than license a finished product.

Newsletters

The most recent piece, published under their own names.

Dr Patrick E. Sewell in The Third StrandThe economics of preventive precision medicine22 Oct 2026

Media reaction

Democratising gene and cell therapy

"Gene and cell therapies are no longer a luxury for the elite. The economies of scale are here, and they're here now. These therapies have real use cases, from the most complex cancers to Alzheimer's and neurodegeneration, and they could transform healthcare systems worldwide. For the first time, preventative healthcare can be democratised on a global scale."

Dr Patrick E. Sewell, Founder and Chief Science Officer, Triple Helix Science20 Oct 2026

Patient experience in gene therapy

"Too often the patient is an afterthought in next-generation medicine. We talk about the science of gene therapy, but far less about what it's like to receive it. Nurse-led care that prepares patients and stays with them for years is one of the gaps we must close if gene therapy is going to reach more people."

Sauny Sewell, Director of Clinical Affairs, Triple Helix Science20 Oct 2026

Longevity, healthspan and preventative care

"'Longevity' is a marketing term. The therapies behind healthspan are not. They're scientifically robust, evidenced and tested, and if our field is going to flourish, that's the story we need to tell. Too many healthcare systems are built on reactive disease management, billing patients for expensive drugs year after year. Patients deserve better, and it's only a matter of time before a preventative model spreads globally."

Dr Patrick E. Sewell, Founder and Chief Science Officer, Triple Helix Science20 Oct 2026

1 of 3

Questions about longevity medicine experts

The questions we get asked most about longevity, answered plainly.

What does a longevity medicine expert actually do?

A longevity medicine expert identifies the cellular and metabolic mechanisms driving age-related decline, then develops and tests therapies that slow or reverse them. At Triple Helix Science that means work on autophagy, genomic stability, telomere integrity, mitochondrial efficiency and insulin sensitivity. The target is healthspan, meaning years lived in good physical and cognitive health, rather than lifespan on its own.

What does a longevity programme with Triple Helix Science involve?

Triple Helix Science works with institutions rather than individuals: governments, sovereign health systems, research universities, sovereign wealth funds and enterprise pharmaceutical organisations. Longevity work is run as proprietary, IP-protected therapeutic protocols taken through to human trials. Because Triple Helix Science treats ageing as systemic, a programme is usually scoped across several of its eight therapeutic areas at once rather than a single pathway.

How do you know whether longevity work is actually having an effect?

Triple Helix Science judges longevity work by healthspan, which is measurable physical and cognitive function, not by years added to lifespan. Metabolic markers including mitochondrial efficiency, insulin sensitivity and lipid balance give readable intermediate signals, alongside autophagy, genomic stability and telomere integrity. The checkable endpoint is human trial data. Triple Helix Science reports completing a Phase 1 human trial showing reversal of dementia progression.

Is longevity medicine the same as anti-ageing treatment?

No. Anti-ageing treatment is sold to individuals and addresses the visible and felt symptoms of getting older. Longevity medicine as practised at Triple Helix Science works on the underlying cellular and metabolic mechanisms of decline, using predictive, genome-based intervention in place of reactive symptom management. Triple Helix Science is not a direct-to-consumer provider and develops protocols for delivery at national scale.

When should an organisation bring in a longevity medicine expert?

Bring one in when an ageing population and rising chronic disease burden are a planning problem, and the question is how to move a health system from reactive symptom management towards genome-based intervention. Pharmaceutical organisations and research universities with a programme to translate are the other common case. An individual seeking personal treatment is not the fit: Triple Helix Science partners with institutions, not consumers.

Contact an expert

Get in touch with an expert on longevity for comment, an interview or a question.

Straight to the Triple Helix Science press team.